William D Figg

List of Publications by Year
in descending order

670 papers	35,247 citations	2544 96 h-index	5679 162 g-index
686 all docs	686 docs citations	686 times ranked	37093 citing authors

#	Article	IF	Citations
1	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	1.6	1,960
2	Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology, 1999, 17, 3461-3467.	1.6	931
3	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 5410-5417.	1.6	687
4	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 545-551.	3.7	624
5	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. Journal of Clinical Oncology, 2015, 33, 74-82.	1.6	571
6	Thalidomide. Lancet, The, 2004, 363, 1802-1811.	13.7	535
7	Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). Clinical Cancer Research, 2005, 11, 4136-4143.	7.0	437
8	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood, 2011, 117, 5827-5834.	1.4	428
9	Antibodyâ€“drug conjugates for cancer. Lancet, The, 2019, 394, 793-804.	13.7	425
10	Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents. Journal of Clinical Oncology, 2004, 22, 2489-2503.	1.6	423
11	Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas. Journal of Clinical Oncology, 2000, 18, 708-708.	1.6	413
12	Angiogenesis Inhibitors: Current Strategies and Future Prospects. Ca-A Cancer Journal for Clinicians, 2010, 60, 222-243.	329.8	413
13	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 2002, 8, 718-28.	7.0	410
14	Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma. Journal of Clinical Oncology, 2005, 23, 3912-3922.	1.6	389
15	Selumetinib in Children with Inoperable Plexiform Neurofibromas. New England Journal of Medicine, 2020, 382, 1430-1442.	27.0	360
16	Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 2532-2539.	1.6	316
17	Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms. Journal of Clinical Oncology, 2001, 19, 2319-2333.	1.6	305
18	Cancer Survivorshipâ€"Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2006, 98, 15-25.	6.3	295

#	Article	IF	Citations
19	Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo. Clinical Cancer Research, 2007, 13, 5183-5194.	7.0	295
20	Drug interactions in cancer therapy. Nature Reviews Cancer, 2006, 6, 546-558.	28.4	290
21	Activity of Thalidomide in AIDS-Related Kaposiâ€™s Sarcoma. Journal of Clinical Oncology, 2000, 18, 2593-2602.	1.6	288
22	Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent. Biochemical Pharmacology, 1998, 55, 1827-1834.	4.4	287
23	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 2007, 109, 2781-2790.	1.4	279
24	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	7.1	266
25	Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives. Current Neuropharmacology, 2006, 4, 165-172.	2.9	251
26	Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. Clinical Cancer Research, 2011, 17, 907-917.	7.0	224
27	Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. Molecular Pharmacology, 2005, 68, 917-932.	2.3	223
28	Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8573-8578.	7.1	220
29	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy, 2010, 10, 997-1008.	2.4	215
30	Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. Clinical Cancer Research, 2006, 12, 5777-5785.	7.0	214
31	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology, 2017, 35, 2193-2202.	1.6	209
32	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates, 2003, 6, 71-84.	14.4	207
33	Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel. Clinical Cancer Research, 2008, 14, 4200-4205.	7.0	204
34	Validation of Analytic Methods for Biomarkers Used in Drug Development. Clinical Cancer Research, 2008, 14, 5967-5976.	7.0	202
35	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biology and Therapy, 2005, 4, 815-818.	3.4	200
36	A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer. Journal of Experimental Therapeutics and Oncology, 2002, 2, 325-332.	0.5	189

#	Article	IF	Citations
37	Scientific Collaboration Results in Higher Citation Rates of Published Articles. Pharmacotherapy, 2006, 26, 759-767.	2.6	187
38	Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. Clinical Cancer Research, 2008, 14, 3312-3318.	7.0	175
39	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2008, 14, 209-214.	7.0	174
40	Pharmacogenetics of irinotecan metabolism and transport: An update. Toxicology in Vitro, 2006, 20, 163-175.	2.4	165
41	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.	1.4	165
42	Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas. Journal of Clinical Oncology, 2003, 21, 2299-2304.	1.6	164
43	Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy. Clinical Cancer Research, 2005, 11, 6823-6834.	7.0	161
44	Effect of ABCG2 genotype on the oral vioavailability of topotecan. Cancer Biology and Therapy, 2005, 4, 650-653.	3.4	161
45	Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses. Journal of the National Cancer Institute, 2014, 106, dju089.	6.3	161
46	A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 4820-4829.	7.0	160
47	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Molecular Cancer Therapeutics, 2009, 8, 2496-2508.	4.1	157
48	Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1083-91.	7.1	156
49	SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2565-2573.	1.6	153
50	A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. Clinical Cancer Research, 2012, 18, 2344-2351.	7.0	151
51	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. European Journal of Cancer, 2006, 42, 2893-2896.	2.8	150
52	Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2807-2813.	2.5	150
53	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clinical Cancer Research, 2011, 17, 569-580.	7.0	149
54	Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1Î± (HIF-1Î±) and p300 by a Zinc Ejection Mechanism. Journal of Biological Chemistry, 2009, 284, 26831-26838.	3.4	148

#	Article	IF	Citations
55	Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. Journal of Clinical Oncology, 2001, 19, 584-592.	1.6	142
56	Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention. Molecular Cancer Research, 2006, 4, 135-150.	3.4	139
57	Coevolution of Prostate Cancer and Bone Stroma in Three-Dimensional Coculture: Implications for Cancer Growth and Metastasis. Cancer Research, 2008, 68, 9996-10003.	0.9	137
58	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1389-1395.	1.6	137
59	Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 2070-2076.	1.6	136
60	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biology and Therapy, 2006, 5, 22-27.	3.4	135
61	Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy. Clinical Cancer Research, 2009, 15, 1411-1416.	7.0	135
62	Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposiâ€™s Sarcoma: A Phase I AIDS Malignancy Consortium Study. Journal of Clinical Oncology, 2002, 20, 153-159.	1.6	134
63	Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resistance Updates, 2004, 7, 195-208.	14.4	132
64	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenetics and Genomics, 2013, 23, 1-8.	1.5	130
65	ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel. Clinical Cancer Research, 2008, 14, 4543-4549.	7.0	127
66	Multiparametric MRI in prostate cancer management. Nature Reviews Clinical Oncology, 2014, 11, 346-353.	27.6	127
67	Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 429-445.	3.3	126
68	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clinical Pharmacology and Therapeutics, 2006, 80, 192-201.	4.7	126
69	Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms. Journal of Clinical Oncology, 2002, 20, 4074-4082.	1.6	125
70	Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development. Annals of Pharmacotherapy, 2002, 36, 905-911.	1.9	125
71	TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opinion on Investigational Drugs, 2000, 9, 1383-1396.	4.1	123
72	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123

#	Article	IF	Citations
73	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clinical Cancer Research, 2011, 17, 6831-6839.	7.0	123
74	Thalidomide metabolism by the CYP2C subfamily. Clinical Cancer Research, 2002, 8, 1964-73.	7.0	123
75	Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. Clinical Cancer Research, 2007, 13, 5411-5417.	7.0	122
76	Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. Journal of Urology, 2008, 179, 2181-2186.	0.4	122
77	The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing. Journal of Surgical Research, 2000, 91, 26-31.	1.6	121
78	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. European Urology, 2008, 54, 1089-1096.	1.9	121
79	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clinical Cancer Research, 2002, 8, 963-70.	7.0	120
80	Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin. Clinical Cancer Research, 2008, 14, 188-198.	7.0	119
81	Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. Cancer Investigation, 2009, 27, 221-226.	1.3	115
82	Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer, 1995, 75, 2932-2938.	4.1	114
83	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics, 2005, 6, 115-138.	1.3	114
84	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. British Journal of Clinical Pharmacology, 2011, 72, 294-305.	2.4	114
85	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. Journal of the National Cancer Institute, 2004, 96, 1585-1592.	6.3	113
86	Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies. Journal of Clinical Oncology, 2005, 23, 3465-3474.	1.6	112
87	Final analysis of a phase II trial using sorafenib for metastatic castrationâ€resistant prostate cancer. BJU International, 2009, 103, 1636-1640.	2.5	112
88	Influence of Genetic Variants inUGT1A1andUGT1A9on the In Vivo Glucuronidation of SN-38. Journal of Clinical Pharmacology, 2004, 44, 854-860.	2.0	107
89	Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncology, The, 2005, 6, 780-789.	10.7	107
90	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell, 2021, 39, 566-579.e7.	16.8	107

#	Article	IF	Citations
91	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology, 2001, 28, 62-66.	2.2	107
92	Using Epigenetic Therapy to Overcome Chemotherapy Resistance. Anticancer Research, 2016, 36, 1-4.	1.1	105
93	Pharmacokinetics of thalidomide in an elderly prostate cancer population. Journal of Pharmaceutical Sciences, 1999, 88, 121-125.	3.3	104
94	COVIDâ€19 Clinical Diagnostics and Testing Technology. Pharmacotherapy, 2020, 40, 857-868.	2.6	104
95	Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. Molecular Biotechnology, 2010, 44, 152-167.	2.4	103
96	Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. Clinical Cancer Research, 2012, 18, 2099-2107.	7.0	103
97	A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU International, 2005, 96, 985-989.	2.5	102
98	Racial Variation in CAG Repeat Lengths Within the Androgen Receptor Gene Among Prostate Cancer Patients of Lower Socioeconomic Status. Journal of Clinical Oncology, 2002, 20, 3599-3604.	1.6	100
99	Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1Î± in Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 5123-5131.	7.0	100
100	Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology. Journal of Clinical Pharmacology, 2005, 45, 394-403.	2.0	99
101	A phase II study of perifosine in androgen independent prostate cancer. Cancer Biology and Therapy, 2005, 4, 1133-1137.	3.4	98
102	Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers. PLoS ONE, 2011, 6, e14504.	2.5	98
103	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	4.2	97
104	Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. Journal of Clinical Oncology, 2001, 19, 832-842.	1.6	95
105	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. Journal of Experimental and Clinical Cancer Research, 2010, 29, 95.	8.6	94
106	Endothelial Monocyte Activating Polypeptide II Induces Endothelial Cell Apoptosis and May Inhibit Tumor Angiogenesis. Microvascular Research, 2000, 60, 70-80.	2.5	91
107	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. Journal of Clinical Oncology, 2016, 34, 4125-4131.	1.6	91
108	Reactive astrocytic S1P3 signaling modulates the bloodâ€“tumor barrier in brain metastases. Nature Communications, 2018, 9, 2705.	12.8	91

#	Article	IF	Citations
109	CYP2D6 polymorphisms and the impact on tamoxifen therapy. Journal of Pharmaceutical Sciences, 2007, 96, 2224-2231.	3.3	89
110	Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression. PLoS ONE, 2011, 6, e20372.	2.5	89
111	Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology, 1998, 52, 252-256.	1.0	88
112	A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1â€“3 inhibitor, cediranib, in recurrent womenâ€™s cancers with biomarker analyses. , 2019, 7, 197.		88
113	Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. American Journal of Medicine, 1995, 98, 412-414.	1.5	87
114	Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor Progression and Therapy. Journal of Clinical Oncology, 2004, 22, 499-506.	1.6	86
115	Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Investigational New Drugs, 2002, 20, 183-194.	2.6	84
116	Endostatin Inhibits Microvessel Formation in the ex Vivo Rat Aortic Ring Angiogenesis Assay. Biochemical and Biophysical Research Communications, 2000, 268, 183-191.	2.1	83
117	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research, 2014, 20, 5392-5402.	7.0	83
118	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. Clinical Cancer Research, 2019, 25, 4945-4954.	7.0	82
119	Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models. Cancer Chemotherapy and Pharmacology, 1998, 42, S54-S59.	2.3	81
120	Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications. Current Drug Metabolism, 2006, 7, 677-685.	1.2	80
121	Relationship of systemic exposure to unbound docetaxel and neutropenia. Clinical Pharmacology and Therapeutics, 2005, 77, 43-53.	4.7	79
122	Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular Cancer Therapeutics, 2008, 7, 19-26.	4.1	79
123	Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer. Journal of Clinical Oncology, 2003, 21, 4356-4363.	1.6	78
124	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. Journal of Clinical Oncology, 2020, 38, 3672-3684.	1.6	78
125	Pharmacodynamic markers and clinical results from the phase 2 study of the <scp>SMAC</scp> mimetic birinapant in women with relapsed platinumâ€resistant or â€refractory epithelial ovarian cancer. Cancer, 2016, 122, 588-597.	4.1	77
126	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	7.3	77

#	Article	IF	Citations
127	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar). Cancer, 2001, 92, 1577-1590.	4.1	76
128	Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics, 2010, 11, 89-103.	1.3	76
129	Precision Oncology Medicine: The Clinical Relevance of Patientâ€Specific Biomarkers Used to Optimize Cancer Treatment. Journal of Clinical Pharmacology, 2016, 56, 1484-1499.	2.0	75
130	Polymorphism in the hypoxia-inducible factor 1Î± gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biology and Therapy, 2005, 4, 1222-1225.	3.4	74
131	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral Tâ€cell lymphoma. British Journal of Haematology, 2010, 148, 256-267.	2.5	74
132	Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1Î±/p300 complex in a preclinical model of prostate cancer. Molecular Cancer, 2014, 13, 91.	19.2	73
133	Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel. Clinical Cancer Research, 2006, 12, 4636-4640.	7.0	72
134	Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Research, 2003, 63, 3189-94.	0.9	72
135	Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anti-Cancer Drugs, 2007, 18, 111-126.	1.4	71
136	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 5038-5047.	7.0	70
137	Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates. ELife, 2019, 8, .	6.0	70
138	A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 4724-4733.	7.0	69
139	Thalidomide Analogues as Anticancer Drugs. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 167-174.	1.6	69
140	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 4633-4641.	7.0	68
141	Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer, 1995, 76, 453-462.	4.1	67
142	Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor ELâ€"Based Paclitaxel. Clinical Cancer Research, 2006, 12, 4331-4338.	7.0	67
143	A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors. Clinical Cancer Research, 2007, 13, 7101-7106.	7.0	66
144	Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. American Journal of Medicine, 1988, 85, 452-453.	1.5	65

#	Article	IF	Citations
145	Apoptosis: Its Role in the Development of Malignancies and its Potential as a Novel Therapeutic Target. Annals of Pharmacotherapy, 1997, 31, 76-82.	1.9	65
146	Taxane-Mediated Antiangiogenesis in Vitro . Cancer Research, 2004, 64, 821-824.	0.9	65
147	Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Therapeutics and Clinical Risk Management, 2005, 1, 107-114.	2.0	65
148	Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients. Clinical Cancer Research, 2005, 11, 7398-7404.	7.0	64
149	Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma. Clinical Cancer Research, 2009, 15, 1496-1503.	7.0	64
150	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12703-12708.	7.1	64
151	An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research, 2014, 20, 5918-5926.	7.0	64
152	Suramin's development: what did we learn?. Investigational New Drugs, 2002, 20, 209-219.	2.6	63
153	TMPRSS2: Potential Biomarker for COVIDâ€19 Outcomes. Journal of Clinical Pharmacology, 2020, 60, 801-807.	2.0	63
154	Effects of the antiestrogen tamoxiten on low-density lipoprotein concentrations and oxidation in postmenopausal women. American Journal of Cardiology, 1995, 76, 1072-1073.	1.6	62
155	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood, 2013, 121, 476-484.	1.4	62
156	Integrating pharmacogenetic information and clinical decision support into the electronic health record. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 522-528.	4.4	61
157	Pharmacogenetic Associations ofCYP2C19Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide. Cancer Biology and Therapy, 2002, 1, 669-673.	3.4	60
158	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU International, 2008, 102, 617-621.	2.5	60
159	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clinical Immunology, 2014, 155, 176-187.	3.2	60
160	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2020, 21, 1099-1109.	10.7	59
161	Resistance to second-generation androgen receptor antagonists in prostate cancer. Nature Reviews Urology, 2021, 18, 209-226.	3.8	59
162	Reversal of Multidrug Resistance: Lessons from Clinical Oncology. Novartis Foundation Symposium, 0, , 83-102.	1.1	59

#	Article	IF	Citations
163	Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2001, 19, 800-811.	1.6	58
164	Thalidomide Metabolites and Analogues. 3. Synthesis and Antiangiogenic Activity of the Teratogenic and TNFÎ±-Modulatory Thalidomide Analogue 2-(2,6-Dioxopiperidine-3-yl)phthalimidine. Journal of Medicinal Chemistry, 2003, 46, 3793-3799.	6.4	58
165	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunology, Immunotherapy, 2013, 62, 299-307.	4.2	58
166	Development of a rapid and sensitive LCâ€“MS/MS assay for the determination of sorafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 362-367.	2.8	57
167	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1724-33.	7.1	57
168	Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. Journal of Controlled Release, 2017, 268, 147-158.	9.9	57
169	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. Clinical Cancer Research, 2013, 19, 4499-4507.	7.0	55
170	Dual Targeting of the Androgen Receptor and Hypoxia-Inducible Factor 1Î± Pathways Synergistically Inhibits Castration-Resistant Prostate Cancer Cells. Molecular Pharmacology, 2015, 87, 1006-1012.	2.3	55
171	A phase <scp>I</scp> study of <scp>TRC</scp>105 antiâ€endoglin (<scp>CD</scp>105) antibody in metastatic castrationâ€resistant prostate cancer. BJU International, 2015, 116, 546-555.	2.5	55
172	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750â€"an antisense oligonucleotide against eIF4Eâ€"in combination with irinotecan in solid tumors and irinotecanâ€refractory colorectal cancer. International Journal of Cancer, 2016, 139, 1648-1657.	5.1	55
173	The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and Barriers of the CNS, 2018, 15, 2.	5.0	55
174	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWSâ€“FLI1 fusion transcript. Cancer Chemotherapy and Pharmacology, 2017, 80, 645-652.	2.3	54
175	Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 1083-1090.	2.0	53
176	Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. Journal of Clinical Pharmacology, 2009, 49, 650-660.	2.0	52
177	Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine. Journal of Clinical Pharmacology, 1995, 35, 368-373.	2.0	51
178	PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA. Oncologist, 2021, 26, e115-e129.	3.7	51
179	Laparoscopic continuous hyperthermic peritoneal perfusion11No competing interests declared.. Journal of the American College of Surgeons, 2001, 193, 225-229.	0.5	50
180	5Â´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis. Therapeutic Drug Monitoring, 2002, 24, 104-110.	2.0	50

#	Article	IF	Citations
181	Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice. Clinical Cancer Research, 2004, 10, 4192-4197.	7.0	50
182	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. Clinical Cancer Research, 2011, 17, 3388-3397.	7.0	49
183	Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Scientific Reports, 2016, 6, 30038.	3.3	48
184	Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 2219-2227.	6.4	47
185	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer, 2010, 10, 511.	2.6	47
186	The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clinical Cancer Research, 2002, 8, 1242-50.	7.0	47
187	Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 181-188.	2.3	46
188	Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1Î±/p300 Interaction. Journal of Natural Products, 2016, 79, 1267-1275.	3.0	46
189	Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clinical Cancer Research, 2017, 23, 1397-1406.	7.0	46
190	Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer. Cancer Investigation, 1996, 14, 513-517.	1.3	45
191	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU International, 2007, 99, 1047-1055.	2.5	45
192	Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 213-218.	2.3	45
193	Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer. Clinical Cancer Research, 2009, 15, 4292-4298.	7.0	45
194	A sensitive and rapid ultra HPLCâ€“MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 880, 132-139.	2.3	45
195	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer and Prostatic Diseases, 2019, 22, 406-410.	3.9	45
196	Disclosing a Diagnosis of Cancer: Where and How Does It Occur?. Journal of Clinical Oncology, 2010, 28, 3630-3635.	1.6	44
197	In vivoscreening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget, 2016, 7, 33237-33245.	1.8	44
198	Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel. Clinical Cancer Research, 2013, 19, 3095-3104.	7.0	43

#	Article	IF	Citations
199	Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened. Journal of Urology, 2014, 192, 379-384.	0.4	43
200	Synergistic targeted inhibition of <scp>MEK</scp> and dual <scp>PI</scp>3K/<scp>mTOR</scp> diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Pigment Cell and Melanoma Research, 2016, 29, 643-655.	3.3	43
201	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 3333-3340.	8.2	43
202	A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer, 1995, 75, 2159-2164.	4.1	42
203	Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. Journal of Clinical Pharmacology, 1996, 36, 206-215.	2.0	42
204	New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis, 1997, 1, 23-35.	7.2	42
205	Approaches to preclinical screening of antiangiogenic agents. Seminars in Oncology, 2001, 28, 570-576.	2.2	42
206	Recent advances in pharmacogenetic approaches to anticancer drug development. Drug Development Research, 2004, 62, 233-253.	2.9	42
207	Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested caseâ€“control study. Cancer Causes and Control, 2011, 22, 1121-1131.	1.8	42
208	Are sex discordant outcomes in COVID-19 related to sex hormones?. Seminars in Oncology, 2020, 47, 335-340.	2.2	42
209	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. Journal of Urology, 2009, 181, 1104-1113.	0.4	41
210	Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discovery Medicine, 2012, 13, 19-34.	0.5	41
211	Pharmacokinetic Studies with Recombinant Cytokines. Clinical Pharmacokinetics, 1997, 32, 368-381.	3.5	40
212	Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis. Journal of Clinical Pharmacology, 1999, 39, 394-401.	2.0	40
213	Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion. Annals of Pharmacotherapy, 2003, 37, 1369-1374.	1.9	40
214	Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation. Journal of the National Cancer Institute, 2010, 102, 1698-1705.	6.3	40
215	Phase <scp>II</scp> clinical trial of cediranib in patients with metastatic castrationâ€resistant prostate cancer. BJU International, 2013, 111, 1269-1280.	2.5	40
216	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 77-85.	1.9	40

#	Article	IF	Citations
217	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. Journal of Clinical Investigation, 2017, 127, 2326-2338.	8.2	40
218	Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nature Biotechnology, 1998, 16, 91-94.	17.5	39
219	Augmentation of Melanoma-Specific Gene Expression Using a Tandem Melanocyte-Specific Enhancer Results in Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene in Melanoma. Human Gene Therapy, 1999, 10, 889-898.	2.7	39
220	Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 686-694.	0.8	39
221	Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemotherapy and Pharmacology, 2006, 57, 275-281.	2.3	39
222	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs, 2018, 29, 457-465.	1.4	39
223	Androgen Receptor CAG Repeat Length and Association With Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Journal of Urology, 2010, 184, 2297-2302.	0.4	38
224	Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. Science Translational Medicine, 2021, 13, eabd8077.	12.4	38
225	Synthesis of Racemiccis-5-Hydroxy-3-phthalimidoglutarimide. A Metabolite of Thalidomide Isolated from Human Plasma. Journal of Organic Chemistry, 2005, 70, 10117-10120.	3.2	37
226	Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacological Research, 2016, 114, 152-162.	7.1	37
227	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	5.2	37
228	EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINES. Journal of Urology, 2000, 163, 1022-1026.	0.4	36
229	A phase II study of TRC105Âin patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterology Journal, 2015, 3, 453-461.	3.8	36
230	A facile scheme for phthalimide â‡Œ phthalimidine conversion. Tetrahedron Letters, 1999, 40, 2087-2090.	1.4	35
231	Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biology and Therapy, 2008, 7, 1004-1005.	3.4	35
232	Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biology and Therapy, 2010, 10, 13-18.	3.4	35
233	Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1Î±. Journal of the American Chemical Society, 2015, 137, 5569-5575.	13.7	35
234	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2020, 26, 828-836.	7.0	35

#	Article	IF	Citations
235	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repairâ€“targeted therapies. Science Translational Medicine, 2021, 13, .	12.4	35
236	A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and Clinical Risk Management, 2010, 6, 579.	2.0	34
237	Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 233-247.	1.8	34
238	Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2â€methoxyestradiol. Journal of Pharmaceutical Sciences, 2007, 96, 1821-1831.	3.3	33
239	Bioluminescent imaging study. Cancer Biology and Therapy, 2010, 10, 38-43.	3.4	33
240	The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 708, 21-27.	1.0	33
241	Inhibition of the HIF1Î±-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). European Journal of Medicinal Chemistry, 2015, 94, 509-516.	5.5	33
242	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. JAMA Oncology, 2018, 4, 1781.	7.1	33
243	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirusâ€“associated multicentric Castleman disease. Blood, 2020, 135, 2316-2319.	1.4	33
244	UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response. Invasion & Metastasis, 1998, 18, 209-218.	0.5	32
245	A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer. Journal of Urology, 2010, 183, 2219-2226.	0.4	32
246	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48â€hour continuous infusion in patients with cancer. Journal of Clinical Pharmacology, 2016, 56, 461-473.	2.0	32
247	Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine, 2018, 16, 336.	4.4	32
248	Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget, 2017, 8, 79175-79187.	1.8	32
249	Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer, 2006, 106, 63-67.	4.1	31
250	Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Molecular Cancer Therapeutics, 2008, 7, 1246-1250.	4.1	31
251	Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatographyâ€“tandem mass spectrometry and its application to hepatic chemoembolization. Journal of Pharmaceutical and Biomedical Analysis, 2012, 62, 140-148.	2.8	31
252	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. Journal of Clinical Pharmacology, 2014, 54, 865-873.	2.0	31

#	Article	IF	Citations
253	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e349-e360.	2.3	31
254	Phase 1 study of the immunotoxin LMBâ€100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer, 2020, 126, 4936-4947.	4.1	31
255	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget, 2014, 5, 8161-8172.	1.8	31
256	Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Human Reproduction, 2003, 18, 1820-1827.	0.9	30
257	Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 806, 305-310.	2.3	30
258	Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate Cancer. Urology, 2007, 70, 217-220.	1.0	30
259	Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. Journal of Organic Chemistry, 2016, 81, 10631-10640.	3.2	30
260	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. Molecular Cancer Therapeutics, 2018, 17, 1694-1704.	4.1	30
261	Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemotherapy and Pharmacology, 1999, 43, S78-S84.	2.3	29
262	A Phase I Study of Oral CC-5013(Lenalidomide, Revlimidâ„¢), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer. Clinical Prostate Cancer, 2004, 2, 241-243.	2.1	29
263	Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Metaâ€Analysis. Oncologist, 2012, 17, 312-320.	3.7	29
264	Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes and Control, 2016, 27, 175-182.	1.8	29
265	Flavopiridol Inversely Affects p21WAF1/CIP1and p53 and Protects p21-Sensitive Cells from Paclitaxel. Cancer Biology and Therapy, 2002, 1, 420-425.	3.4	28
266	Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood, 2006, 108, 4126-4135.	1.4	28
267	Estrogen Receptor Î± and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E368-E372.	3.6	28
268	A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 714-723.	2.6	28
269	Insulin-Like Growth Factors and Insulin-Like Growth Factorâ€"Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2013, 6, 91-99.	1.5	28
270	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Molecular Cancer Therapeutics, 2015, 14, 2228-2237.	4.1	28

#	Article	IF	Citations
271	Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti-Cancer Drugs, 2003, 14, 125-135.	1.4	27
272	Effects of Î±1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine. Clinical Cancer Research, 2004, 10, 6840-6846.	7.0	27
273	Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. Expert Review of Anticancer Therapy, 2005, 5, 605-611.	2.4	27
274	A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology, 2010, 65, 383-389.	2.3	27
275	A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 154-161.	2.3	27
276	ANG1005 for breast cancer brain metastases: correlation between 18F-FLTâ€“PET after first cycle and MRI in response assessment. Breast Cancer Research and Treatment, 2016, 160, 51-59.	2.5	27
277	Pharmacogenomics and histone deacetylase inhibitors. Pharmacogenomics, 2016, 17, 1807-1815.	1.3	27
278	Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. PLoS ONE, 2015, 10, e0126672.	2.5	27
279	Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer. Current Drug Metabolism, 2003, 4, 505-513.	1.2	27
280	Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer, 1994, 74, 1612-1614.	4.1	26
281	Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance. PLoS ONE, 2014, 9, e95532.	2.5	26
282	BET bromodomain inhibitorsâ€”A novel epigenetic approach in castration-resistant prostate cancer. Cancer Biology and Therapy, 2014, 15, 1583-1585.	3.4	26
283	Phase I Trial of Bortezomib (PS-341; NSC 681239) and â€œNonhybridâ€•(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical Cancer Research, 2014, 20, 5652-5662.	7.0	26
284	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Clinical Cancer Research, 2020, 26, 704-716.	7.0	26
285	Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma. Mayo Clinic Proceedings, 1999, 74, 137-145.	3.0	25
286	Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anti-Cancer Drugs, 2008, 19, 275-281.	1.4	25
287	Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy. Cancer Biology and Therapy, 2013, 14, 90-91.	3.4	25
288	Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. Clinical Cancer Research, 2016, 22, 1197-1210.	7.0	25

#	Article	IF	Citations
289	Opportunities for using in silicoâ€based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1769-1777.	2.4	25
290	Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer Biology and Therapy, 2006, 5, 909-911.	3.4	24
291	Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clinical Cancer Research, 2003, 9, 562-70.	7.0	24
292	A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Analytica Chimica Acta, 1997, 339, 91-97.	5.4	23
293	Histone deacetylase inhibitors are potent radiation protectants. Cancer Biology and Therapy, 2004, 3, 612-613.	3.4	23
294	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU International, 2008, 101, 884-888.	2.5	23
295	Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate:in vivoevidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2284-2292.	1.3	23
296	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. Clinical Genitourinary Cancer, 2013, 11, 229-237.	1.9	23
297	Phase <scp>II</scp> trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castrationâ€resistant prostate cancer. BJU International, 2016, 118, 590-597.	2.5	23
298	Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. Cytokine, 2018, 108, 213-224.	3.2	23
299	Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. Molecular Pharmacology, 2019, 96, 158-167.	2.3	23
300	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
301	Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. American Journal of Hematology, 2001, 67, 51-53.	4.1	22
302	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU International, 2008, 102, 1694-1699.	2.5	22
303	The Role of MRI in Prostate Cancer Active Surveillance. BioMed Research International, 2014, 2014, 1-6.	1.9	22
304	A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. Journal of Pharmaceutical and Biomedical Analysis, 2014, 92, 63-68.	2.8	22
305	Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. Pharmacogenetics and Genomics, 2017, 27, 159-163.	1.5	22
306	Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat. ChemMedChem, 2021, 16, 2082-2088.	3.2	22

#	Article	IF	Citations
307	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. PLoS ONE, 2016, 11, e0152007.	2.5	22
308	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. Oncologist, 2022, 27, e273-e285.	3.7	22
309	Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatographyâ€“electrospray mass spectrometry. Biomedical Applications, 2001, 759, 247-257.	1.7	21
310	Secondary hormonal therapy for prostate cancer: what lies on the horizon?. BJU International, 2008, 101, 271-274.	2.5	21
311	Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biology and Therapy, 2010, 9, 341-342.	3.4	21
312	CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Frontiers in Oncology, 2015, 5, 123.	2.8	21
313	Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models. Marine Drugs, 2018, 16, 241.	4.6	21
314	Structureâ€Activity Relationship and Crystallographic Studies on 4â€Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors. ChemMedChem, 2020, 15, 270-273.	3.2	21
315	Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Molecular Cancer Therapeutics, 2003, 2, 845-54.	4.1	21
316	A Preliminary Risk-Benefit Assessment of Paclitaxel. Drug Safety, 1995, 12, 196-208.	3.2	20
317	High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2000, 22, 1003-1014.	2.8	20
318	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2003, 169, 357-360.	0.4	20
319	Small Molecule-Mediated Anti-Cancer Therapy via Hypoxia Inducible Factor-1 Blockade. Cancer Biology and Therapy, 2004, 3, 503-504.	3.4	20
320	Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Investigational New Drugs, 2006, 24, 367-375.	2.6	20
321	ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anti-Cancer Drugs, 2007, 18, 563-568.	1.4	20
322	Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer, 2016, 122, 2332-2340.	4.1	20
323	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. Molecular Cancer Research, 2017, 15, 1096-1105.	3.4	20
324	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. Oncologist, 2017, 22, 505-e49.	3.7	20

#	Article	IF	Citations
325	Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. Methods in Molecular Biology, 2014, 1175, 91-120.	0.9	20
326	Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 811, 135-141.	2.3	20
327	Treatment options for androgen-independent prostate cancer. Clinical Advances in Hematology and Oncology, 2003, 1, 49-57.	0.3	20
328	The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. , 1996, 29, 177-182.		19
329	Initial Pharmacokinetics and Bioavailability of PSC 833, a Pâ€Glycoprotein Antagonist. Journal of Clinical Pharmacology, 1997, 37, 123-128.	2.0	19
330	A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer. Urologia Internationalis, 1999, 63, 120-125.	1.3	19
331	The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 153-159.	2.1	19
332	Mechanisms of Disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. Nature Reviews Urology, 2005, 2, 101-107.	1.4	19
333	Importance of the Stress Kinase p38Î± in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells. Clinical Cancer Research, 2006, 12, 3502-3509.	7.0	19
334	Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience. Cancer Prevention Research, 2010, 3, 1523-1533.	1.5	19
335	Impact ofABCB1Allelic Variants on QTc Interval Prolongation. Clinical Cancer Research, 2011, 17, 937-946.	7.0	19
336	Prostate cancer progression attributed to autonomic nerve development. Cancer Biology and Therapy, 2013, 14, 1005-1006.	3.4	19
337	UGT1A1 genotypeâ€dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. Journal of Clinical Pharmacology, 2016, 56, 450-460.	2.0	19
338	Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. Journal of Clinical Pharmacology, 2017, 57, S67-S77.	2.0	19
339	Mifepristone: Antineoplastic Studies. Clinical Obstetrics and Gynecology, 1996, 39, 498-505.	1.1	19
340	Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. Anticancer Research, 2003, 23, 3585-90.	1.1	19
341	A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer. Acta OncolÃ³gica, 2003, 42, 195-201.	1.8	18
342	Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2. Annals of Pharmacotherapy, 2010, 44, 1709-1717.	1.9	18

#	Article	IF	Citations
343	A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application. Chromatography (Basel), 2014, 1, 82-95.	1.2	18
344	Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro . International Journal of Nanomedicine, 2020, Volume 15, 991-1003.	6.7	18
345	The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer. Urologia Internationalis, 2002, 68, 16-23.	1.3	17
346	Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 806, 289-293.	2.3	17
347	Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Prostate, 2010, 70, 584-590.	2.3	17
348	Monitor tumor burden with circulating tumor DNA. Cancer Biology and Therapy, 2013, 14, 697-698.	3.4	17
349	Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatric Blood and Cancer, 2015, 62, 603-610.	1.5	17
350	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. Clinical Cancer Research, 2019, 25, 4238-4247.	7.0	17
351	ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biology and Therapy, 2006, 5, 254-255.	3.4	16
352	Hormone-Refractory Prostate Cancer. Drugs, 2007, 67, 1109-1124.	10.9	16
353	The Genetics of Castration-Resistant Prostate Cancer: What Can the Germline Tell Us?. Clinical Cancer Research, 2008, 14, 4691-4693.	7.0	16
354	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 31.e25-31.e33.	1.6	16
355	Evaluation of entinostat alone and in combination with standardâ€ofâ€care cytotoxic agents against rhabdomyosarcoma xenograft models. Pediatric Blood and Cancer, 2019, 66, e27820.	1.5	16
356	Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 438-451.	2.5	16
357	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1171, 122641.	2.3	16
358	The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. Translational Cancer Research, 2016, 5, S1107-S1110.	1.0	16
359	In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. Cancer Letters, 1997, 113, 111-116.	7.2	15
360	Pharmacy Education: Back to the Basics?. Pharmacotherapy, 2003, 23, 1381-1390.	2.6	15

#	Article	IF	Citations
361	Immunomodulation of multiple myeloma. Cancer Biology and Therapy, 2004, 3, 1060-1061.	3.4	15
362	Angiogenesis and prostate cancer: Important laboratory and clinical findings. Current Oncology Reports, 2005, 7, 215-219.	4.0	15
363	Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. European Urology, 2007, 52, 1020-1027.	1.9	15
364	Development and Validation of an LC-MS Assay for Finasteride and its Application to Prostate Cancer Prevention Trial Sample Analysis. Journal of Chromatographic Science, 2008, 46, 356-361.	1.4	15
365	More than an accessory: implications of type III transforming growth factorâ€Î² receptor loss in prostate cancer. BJU International, 2010, 105, 913-916.	2.5	15
366	Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. Cancer Biology and Therapy, 2014, 15, 1586-1587.	3.4	15
367	A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemotherapy and Pharmacology, 2014, 74, 955-967.	2.3	15
368	Genetic variation: effect on prostate cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 446-456.	7.4	15
369	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 137, 896-907.	1.4	15
370	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research, 2021, 27, 3298-3306.	7.0	15
371	Plasma Protein Binding of Phenylacetate and Phenylbutyrate, Two Novel Antineoplastic Agents. Therapeutic Drug Monitoring, 1996, 18, 714-720.	2.0	15
372	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomedical Chromatography, 2000, 14, 338-343.	1.7	14
373	Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. Cancer Biology and Therapy, 2004, 3, 719-720.	3.4	14
374	Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World Journal of Urology, 2004, 22, 425-430.	2.2	14
375	Associations of Serum Sex Steroid Hormone and 5Î±-Androstane-3Î±,17Î²-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1823-1832.	2.5	14
376	Bcl-2 Family of Proteins as Therapeutic Targets in Genitourinary Neoplasms. Clinical Genitourinary Cancer, 2013, 11, 10-19.	1.9	14
377	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-Î± and angiogenesis inhibitory activities. Bioorganic and Medicinal Chemistry, 2018, 26, 1547-1559.	3.0	14
378	Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis, 2018, 39, 125-133.	2.8	14

#	Article	IF	Citations
379	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 2308-2318.	4.1	14
380	Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer. Southern Medical Journal, 2015, 108, 224-228.	0.7	14
381	Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. Journal of Pediatric Pharmacology and Therapeutics, 2014, 19, 16-24.	0.5	14
382	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. Journal of Clinical Pharmacology, 2022, 62, 532-540.	2.0	14
383	Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-Î³-hydroxyglutamic acid. Tetrahedron Letters, 2000, 41, 2275-2278.	1.4	13
384	Phase I Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura. Clinical Lung Cancer, 2002, 4, 186-192.	2.6	13
385	Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. Expert Opinion on Therapeutic Patents, 2004, 14, 215-229.	5.0	13
386	Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biology and Therapy, 2004, 3, 1298-1303.	3.4	13
387	Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatographyâ€“electrospray mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 804, 289-294.	2.3	13
388	Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology, 2005, 66, 571-576.	1.0	13
389	The use of thalidomide in androgen-independent prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 246-249.	1.6	13
390	Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 865, 153-158.	2.3	13
391	CHIP and gp78-mediated ubiquitination of CYP3A4. Cancer Biology and Therapy, 2011, 11, 549-551.	3.4	13
392	UGT genotyping in belinostat dosing. Pharmacological Research, 2016, 105, 22-27.	7.1	13
393	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 247-257.	2.8	13
394	Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. FASEB Journal, 2020, 34, 11395-11404.	0.5	13
395	Stem cell clinics: risk of proliferation. Lancet Oncology, The, 2020, 21, 205-206.	10.7	13
396	Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. Molecular Cancer Therapeutics, 2021, 20, 915-924.	4.1	13

#	Article	IF	Citations
397	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. Cancers, 2021, 13, 2154.	3.7	13
398	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget, 2019, 10, 2855-2868.	1.8	13
399	Lutetium-177-PSMA-617: A Vision of the Future. Cancer Biology and Therapy, 2022, 23, 186-190.	3.4	13
400	Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies. Journal of Clinical Pharmacology, 2003, 43, 1124-1135.	2.0	12
401	Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of TaxolÂ® and PaxeneÂ®. Cancer Biology and Therapy, 2005, 4, 555-560.	3.4	12
402	Combinatorial Antileukemic Disruption of Oxidative Homeostasis and Mitochondrial Stability by the Redox Reactive Thalidomide 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and Flavopiridol. Molecular Pharmacology, 2008, 74, 872-883.	2.3	12
403	Angiogenesis inhibitors increase tumor stem cells. Cancer Biology and Therapy, 2012, 13, 586-587.	3.4	12
404	Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomarkers in Medicine, 2013, 7, 831-841.	1.4	12
405	Epigenetic approaches to overcoming chemotherapy resistance. Lancet Oncology, The, 2015, 16, 1013-1015.	10.7	12
406	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
407	Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. Journal of Neuro-Oncology, 2017, 132, 401-407.	2.9	12
408	Precision medicine applications in prostate cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	3.2	12
409	PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release, 2019, 308, 86-97.	9.9	12
410	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113073.	2.8	12
411	Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures. Molecular Cancer Research, 2020, 18, 1278-1289.	3.4	12
412	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	7.1	12
413	Vertical Inhibition of the RAFâ€“MEKâ€“ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression inH/NRASQ61XMutant Rhabdomyosarcoma. Molecular Cancer Therapeutics, 2022, 21, 170-183.	4.1	12
414	Peripheral Neuropathy in HIV Patient after Isoniazid Therapy Initiated. DICP: the Annals of Pharmacotherapy, 1991, 25, 100-101.	0.2	11

#	Article	IF	Citations
415	Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. Tetrahedron Letters, 2000, 41, 7151-7155.	1.4	11
416	Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. Clinical Pharmacology and Therapeutics, 2003, 74, 509-510.	4.7	11
417	Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapy. Cancer Biology and Therapy, 2004, 3, 1212-1213.	3.4	11
418	Cyclooxygenase-2 and angiogenesis in prostate cancer. Cancer Biology and Therapy, 2005, 4, 813-814.	3.4	11
419	The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor. Chemotherapy Research and Practice, 2011, 2011, 1-8.	1.6	11
420	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma, 2017, 58, 639-645.	1.3	11
421	Vertebrate embryos as tools for anti-angiogenic drug screening and function. Reproductive Toxicology, 2017, 70, 49-59.	2.9	11
422	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. Molecules, 2020, 25, 5683.	3.8	11
423	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clinical Genitourinary Cancer, 2020, 18, 258-267.e1.	1.9	11
424	On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. Biochemical and Biophysical Research Communications, 2021, 534, 67-72.	2.1	11
425	Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treatment Reviews, 1996, 22, 105-118.	7.7	10
426	Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer. Acta OncolÃ³gica, 1996, 35, 763-765.	1.8	10
427	Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one. , 1996, 51, 152-157.		10
428	Antiangiogenesis: A Possible Treatment Option for Prostate Cancer?. Clinical Genitourinary Cancer, 2005, 4, 197-202.	1.9	10
429	Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. Anti-Cancer Drugs, 2006, 17, 977-983.	1.4	10
430	Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine. Clinical Cancer Research, 2014, 20, 2525-2529.	7.0	10
431	Synthesis of a stable and orally bioavailable englerin analogue. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2641-2644.	2.2	10
432	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer Biology and Therapy, 2020, 21, 223-230.	3.4	10

#	Article	IF	Citations
433	Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemotherapy and Pharmacology, 2020, 85, 827-830.	2.3	10
434	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 475-486.	2.3	10
435	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. Cancer Research, 2021, 81, 1076-1086.	0.9	10
436	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist, 2021, 26, 288-e541.	3.7	10
437	Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Scientific Reports, 2021, 11, 10765.	3.3	10
438	Adenosine A2A Receptor Activation Enhances Bloodâ€“Tumor Barrier Permeability in a Rodent Glioma Model. Molecular Cancer Research, 2021, 19, 2081-2095.	3.4	10
439	Determination of fraction unbound docetaxel using microequilibrium dialysis. Analytical Biochemistry, 2004, 331, 192-194.	2.4	10
440	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood, 2020, 136, 43-45.	1.4	10
441	Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. Blood, 2008, 112, 1568-1568.	1.4	10
442	Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. Blood, 2014, 124, 2105-2105.	1.4	10
443	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2022, 28, 1353-1362.	7.0	10
444	The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Clinical Pharmacology and Therapeutics, 2006, 79, 1-8.	4.7	9
445	Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatographyâ€“electrospray mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 830, 35-40.	2.3	9
446	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. International Journal of Cancer, 2009, 125, 1143-1146.	5.1	9
447	A rapid ultra HPLCâ€“MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 927, 142-146.	2.3	9
448	Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology and Therapy, 2015, 16, 1014-1018.	3.4	9
449	Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids. ChemMedChem, 2016, 11, 2621-2629.	3.2	9
450	The canSAR data hub for drug discovery. Lancet Oncology, The, 2016, 17, 286.	10.7	9

#	Article	IF	Citations
451	Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory womenâ€™s cancers. Cancer Chemotherapy and Pharmacology, 2017, 80, 165-175.	2.3	9
452	Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 521-536.	1.8	9
453	A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1086, 56-62.	2.3	9
454	Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. Cancer Chemotherapy and Pharmacology, 2020, 85, 1003-1007.	2.3	9
455	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
456	Checkpoint inhibitor immunotherapy during pregnancy for relapsedâ€“refractory Hodgkin lymphoma. American Journal of Hematology, 2022, 97, 833-838.	4.1	9
457	National Cancer Institute Intramural Approach to Advanced Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 153-162.	2.1	8
458	A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. Biomedical Chromatography, 2002, 16, 379-382.	1.7	8
459	Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biology and Therapy, 2008, 7, 412-415.	3.4	8
460	A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. Cancer Biology and Therapy, 2009, 8, 1800-1805.	3.4	8
461	Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. American Journal of Therapeutics, 2010, 17, 176-181.	0.9	8
462	A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting. Cancer Biology and Therapy, 2010, 9, 583-584.	3.4	8
463	Reply to Dâ€™Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4820.	7.1	8
464	Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease. Urology, 2015, 85, 616-620.	1.0	8
465	Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. Separations, 2016, 3, 4.	2.4	8
466	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clinical and Translational Oncology, 2016, 18, 653-659.	2.4	8
467	Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors. MedChemComm, 2019, 10, 500-504.	3.4	8
468	Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?. Cancer Biology and Therapy, 2020, 21, 1-3.	3.4	8

#	Article	IF	Citations
469	Genomeâ€wide Association Study Identified Chromosome 8 Locus Associated with Medicationâ€Related Osteonecrosis of the Jaw. Clinical Pharmacology and Therapeutics, 2021, 110, 1558-1569.	4.7	8
470	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, e15786-e15786.	1.6	8
471	Ibrutinibâ€™s off-target mechanism: cause for dose optimization. Cancer Biology and Therapy, 2021, 22, 529-531.	3.4	8
472	Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. Endocrine-Related Cancer, 2022, 29, 99-109.	3.1	8
473	A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid Chromatography. Journal of Liquid Chromatography and Related Technologies, 1994, 17, 2895-2900.	1.0	7
474	In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anti-Cancer Drugs, 1994, 5, 336-342.	1.4	7
475	PHARMACOKINETICS OF ELEMENTAL PLATINUM (ULTRAFILTRATE AND TOTAL) AFTER A THIRTY MINUTE INTRAVENOUS INFUSION OF ORMAPLATIN. , 1997, 18, 347-359.		7
476	Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 673-687.	0.6	7
477	The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. Oncology Issues, 2000, 15, 23-27.	0.1	7
478	Mutations in the EGFR: The Importance of Genotyping. Cancer Biology and Therapy, 2004, 3, 434-435.	3.4	7
479	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU International, 2007, 99, 525-528.	2.5	7
480	Extraction of DNA from Serum for High-Throughput Genotyping: Findings from Pilot Studies Within the Prostate Cancer Prevention Trial. Urology, 2008, 71, 967-970.	1.0	7
481	Cabazitaxel. Cancer Biology and Therapy, 2010, 10, 1233-1234.	3.4	7
482	Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?. BMJ Open, 2013, 3, e002030.	1.9	7
483	Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLCâ€“MS/MS method for clinical pharmacokinetic application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 970, 95-101.	2.3	7
484	Revisiting 5Î±-reductase inhibitors and the risk of prostate cancer. Nature Reviews Urology, 2018, 15, 400-401.	3.8	7
485	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. Prostate, 2020, 80, 336-344.	2.3	7
486	Cabozantinib plus docetaxel and prednisone in metastatic castrationâ€resistant prostate cancer. BJU International, 2021, 127, 435-444.	2.5	7

#	Article	IF	Citations
487	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 176-176.	1.6	7
488	A Chiral Pool Approach toward the Synthesis of Thalidomide Metabolites. Heterocycles, 2006, 70, 321.	0.7	7
489	Leptomeningeal Carcinomatosis in Metastatic Prostate Cancer. Southern Medical Journal, 2002, 95, 107.	0.7	6
490	Antiangiogenesis therapeutic strategies in prostate cancer. Cancer and Metastasis Reviews, 2002, 21, 93-106.	5.9	6
491	Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 81-86.	2.3	6
492	Randomized discontinuation trial of sorafenib (BAY 43-9006). Cancer Biology and Therapy, 2006, 5, 1270-1272.	3.4	6
493	Uncovering the genetic landscape driving castration-resistant prostate cancer. Cancer Biology and Therapy, 2013, 14, 399-400.	3.4	6
494	Androgen Receptor CAG Repeat Length andÂTMPRSS2:ETS Prostate Cancer Risk:ÂResults From the Prostate Cancer Prevention Trial. Urology, 2014, 84, 127-131.	1.0	6
495	Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. Pharmacogenomics, 2016, 17, 1979-1986.	1.3	6
496	Cellular identity crisis: Antiandrogen resistance by lineage plasticity. Cancer Biology and Therapy, 2017, 18, 841-842.	3.4	6
497	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer Chemotherapy and Pharmacology, 2018, 82, 565-570.	2.3	6
498	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. PLoS ONE, 2019, 14, e0212097.	2.5	6
499	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. Journal of Human Genetics, 2019, 64, 545-550.	2.3	6
500	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. International Journal of Molecular Sciences, 2020, 21, 896.	4.1	6
501	Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models. Neuro-Oncology Advances, 2020, 2, vdaa005.	0.7	6
502	Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.. Blood, 2006, 108, 2469-2469.	1.4	6
503	Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study. Blood, 2014, 124, 4746-4746.	1.4	6
504	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 314-314.	1.6	6

#	Article	IF	Citations
505	A modeling and simulation study of less frequent dosing of nivolumab 480 mg.. Journal of Clinical Oncology, 2019, 37, 3115-3115.	1.6	6
506	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology, 2020, 38, 105-105.	1.6	6
507	Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 331-344.	0.3	5
508	The role of drug-metabolising enzymes in clinical responses to chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 17-25.	3.3	5
509	Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 302-306.	2.3	5
510	Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 355-359.	2.3	5
511	Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide. Clinical Genitourinary Cancer, 2009, 7, E37-E38.	1.9	5
512	Prostate cancer genomic signature offers prognostic value. Cancer Biology and Therapy, 2010, 10, 1079-1080.	3.4	5
513	Significant addition to treatment options for bone metastasis in prostate cancer. Cancer Biology and Therapy, 2012, 13, 69-70.	3.4	5
514	How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer. Cancer Biology and Therapy, 2012, 13, 1141-1142.	3.4	5
515	Multiparametric Magnetic Resonance Imaging of the Prostate Aids to Detect Lesion Progression. Journal of Computer Assisted Tomography, 2014, 38, 565-567.	0.9	5
516	Effect of 5Î±-Reductase Inhibitor Use on Mortality From Prostate Cancer. JAMA Oncology, 2015, 1, 321.	7.1	5
517	Targeted PI3KÎ´ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. Cancer Biology and Therapy, 2015, 16, 204-206.	3.4	5
518	Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?. Cancer Biology and Therapy, 2016, 17, 467-469.	3.4	5
519	<scp>CPS</scp>49â€induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos. Journal of Anatomy, 2018, 232, 568-574.	1.5	5
520	Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides. ChemMedChem, 2018, 13, 2080-2089.	3.2	5
521	A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy. Pharmaceutics, 2021, 13, 997.	4.5	5
522	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 207-207.	1.6	5

#	Article	IF	Citations
523	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.. Journal of Clinical Oncology, 2020, 38, 11540-11540.	1.6	5
524	Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. Oncology Reports, 2006, 15, 519-24.	2.6	5
525	Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis. Cancer Biology and Therapy, 2008, 7, 1386-1387.	3.4	4
526	Androgen receptor sequence and variations in several common prostate cancer cell lines. Cancer Biology and Therapy, 2010, 9, 383-388.	3.4	4
527	Loss of OATP1B3 function causes Rotor syndrome. Cancer Biology and Therapy, 2012, 13, 1374-1375.	3.4	4
528	Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Investigational New Drugs, 2012, 30, 90-97.	2.6	4
529	Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biology and Therapy, 2014, 15, 1296-1298.	3.4	4
530	Evaluating immune responses after sipuleucel-T therapy. Cancer Biology and Therapy, 2015, 16, 1119-1121.	3.4	4
531	Building a hit list for the fight against metastatic castration resistant prostate cancer. Cancer Biology and Therapy, 2016, 17, 231-232.	3.4	4
532	Pharmacokinetics of Pomalidomide in aÂPatient Receiving Hemodialysis Using aÂHigh-Cutoff Filter. American Journal of Kidney Diseases, 2017, 69, 553-554.	1.9	4
533	Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. Cancer Biology and Therapy, 2017, 18, 470-472.	3.4	4
534	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 759-770.	2.3	4
535	Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 19-22.	0.5	4
536	Case report: severe toxicity in an Africanâ€“American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. Pharmacogenomics, 2021, 22, 81-85.	1.3	4
537	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. Blood, 2016, 128, 4527-4527.	1.4	4
538	Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.. Journal of Clinical Oncology, 2012, 30, 64-64.	1.6	4
539	Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis. Journal of Pediatric Pharmacology and Therapeutics, 2018, 23, 106-110.	0.5	4
540	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. Cell Death and Disease, 2022, 13, 410.	6.3	4

#	Article	IF	Citations
541	An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC. Analytical Letters, 1997, 30, 2009-2021.	1.8	3
542	Piecing together the HIF-1 puzzle: The role of the CTGF as a molecular mechanism of HIF-1 regulation. Cancer Biology and Therapy, 2006, 5, 1443-1444.	3.4	3
543	Genetic stability of tumor microenvironment. Cancer Biology and Therapy, 2008, 7, 331-332.	3.4	3
544	shRNA technology: Investigating Ras-dependent cancer. Cancer Biology and Therapy, 2009, 8, 1798-1799.	3.4	3
545	Survivin Is Not Induced by Novel Taxanes. Molecular Pharmaceutics, 2010, 7, 2216-2223.	4.6	3
546	Prolonged low intensity EPOCHâ€“rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. Cancer Biology and Therapy, 2014, 15, 1117-1119.	3.4	3
547	Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation. Cancer Biology and Therapy, 2014, 15, 1293-1295.	3.4	3
548	Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?. Cancer Biology and Therapy, 2015, 16, 19-20.	3.4	3
549	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemotherapy and Pharmacology, 2017, 80, 217-221.	2.3	3
550	Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics. Cancer Biology and Therapy, 2018, 19, 953-955.	3.4	3
551	Antineoplastons: when is enough enough?. Lancet Oncology, The, 2018, 19, 733-734.	10.7	3
552	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports, 2019, 9, 14884.	3.3	3
553	Insulin potentiation therapy for cancer?. Lancet Oncology, The, 2019, 20, 191-192.	10.7	3
554	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. Vox Sanguinis, 2021, 116, 141-154.	1.5	3
555	Facebook groups for alternative treatments for cancer: advertising masquerading as community support. Lancet Oncology, The, 2021, 22, 25-26.	10.7	3
556	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. Journal of Clinical Oncology, 2021, 39, TPS4599-TPS4599.	1.6	3
557	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.. Journal of Clinical Oncology, 2021, 39, 3051-3051.	1.6	3
558	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5096-TPS5096.	1.6	3

#	Article	IF	Citations
559	The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?. Lancet Oncology, The, 2021, 22, 915-916.	10.7	3
560	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	1.5	3
561	Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.. Blood, 2005, 106, 1102-1102.	1.4	3
562	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. Journal of Clinical Oncology, 2020, 38, 11552-11552.	1.6	3
563	Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer. Current Pharmaceutical Biotechnology, 2015, 16, 553-563.	1.6	3
564	Alemtuzumab clearance, lymphocyte count, and Tâ€¢cell chimerism after hematopoietic stem cell transplant in sickle cell disease. Pharmacotherapy, 2022, 42, 14-22.	2.6	3
565	Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. Blood, 2019, 134, 4096-4096.	1.4	3
566	Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques (Macaca mulatta) Based on the Pharmacokinetics of Intrathecally Administered Inulin. Comparative Medicine, 2020, 70, 526-531.	1.0	3
567	Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Research, 2012, 32, 2391-8.	1.1	3
568	Dose Optimization of Pembrolizumab: Less May Be More. Clinical Pharmacology and Therapeutics, 2022, 111, 993-993.	4.7	3
569	Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome. Cancer Biology and Therapy, 2022, 23, 136-138.	3.4	3
570	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. Journal of Clinical Oncology, 2022, 40, 93-93.	1.6	3
571	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. Oncologist, 2022, 27, 718-e694.	3.7	3
572	Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report. Prostate Journal, 1999, 1, 99-102.	0.2	2
573	hTert-Immortalized Endothelial Cells: An Important New Research Tool. Cell Cycle, 2004, 3, 787-787.	2.6	2
574	Upregulation of the Androgen Receptor during Prostate Cancer Progression. Cancer Biology and Therapy, 2004, 3, 284-285.	3.4	2
575	The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. Cancer Biology and Therapy, 2006, 5, 1094-1095.	3.4	2
576	Private Practice Administrative Costs Influenced by Insurance Payer Mix. Journal of Oncology Practice, 2009, 5, 291-297.	2.5	2

#	Article	IF	Citations
577	Genetic variant associated with aggressive not indolent prostate cancer. Cancer Biology and Therapy, 2010, 9, 957-958.	3.4	2
578	Androgen synthesis and steroid transporters in prostate cancer: Rethinking the transition to CRPC. Cancer Biology and Therapy, 2010, 9, 1043-1045.	3.4	2
579	Reply to C. Nabhan et al. Journal of Clinical Oncology, 2011, 29, e147-e147.	1.6	2
580	Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. Cancer Biology and Therapy, 2012, 13, 237-238.	3.4	2
581	The androgen receptor transcriptional program in castration-resistant prostate cancer. Cancer Biology and Therapy, 2014, 15, 16-18.	3.4	2
582	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Cancer Chemotherapy and Pharmacology, 2017, 79, 215-218.	2.3	2
583	Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients. Cancer Biology and Therapy, 2017, 18, 545-546.	3.4	2
584	Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance. Cancer Biology and Therapy, 2018, 19, 869-870.	3.4	2
585	Local and Systemic Antitumor Effects of Photoâ€activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Photochemistry and Photobiology, 2020, 96, 668-679.	2.5	2
586	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. Cancer Biology and Therapy, 2020, 21, 884-887.	3.4	2
587	Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. Scientific Reports, 2021, 11, 5662.	3.3	2
588	Study to Compare Capsule and Liquid Formulations of Enzalutamide After <scp>Single-Dose</scp> Administration Under Fasting Conditions in Prostate Cancer. Oncologist, 2021, 26, 729-e1493.	3.7	2
589	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. Blood, 2018, 132, 1957-1957.	1.4	2
590	A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 117-117.	1.6	2
591	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. Journal of Clinical Oncology, 2013, 31, 10588-10588.	1.6	2
592	A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 173-173.	1.6	2
593	Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.. Journal of Clinical Oncology, 2019, 37, 241-241.	1.6	2
594	Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 130-130.	1.6	2

#	Article	IF	Citations
595	Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 135-140.	2.3	1
596	Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics. Cancer Biology and Therapy, 2006, 5, 840-841.	3.4	1
597	Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation. Current Cancer Therapy Reviews, 2006, 2, 223-229.	0.3	1
598	Temporal-Mediated FGFR1 independence: Implications for targeting candidate molecules in prostate cancer. Cancer Biology and Therapy, 2008, 7, 1180-1181.	3.4	1
599	A genomic strategy for predicting androgen receptor activity in prostate tumors. Cancer Biology and Therapy, 2009, 8, 2002-2003.	3.4	1
600	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3187-3192.	2.3	1
601	Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism. Cancer Biology and Therapy, 2010, 9, 163-165.	3.4	1
602	Aflibercept in Pediatric Solid Tumors: Moving Beyond the Trap. Clinical Cancer Research, 2012, 18, 4868-4871.	7.0	1
603	Preformulation Study of NSC-726796. AAPS PharmSciTech, 2012, 13, 661-673.	3.3	1
604	A novel uHPLCâ€“MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 942-943, 107-112.	2.3	1
605	New mechanism of lenalidomide activity. Cancer Biology and Therapy, 2014, 15, 968-969.	3.4	1
606	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. Cancer Biology and Therapy, 2017, 18, 203-204.	3.4	1
607	Jumping the Barrier: Modeling Drug Penetration across the Bloodâ€“Brain Barrier. Clinical Cancer Research, 2017, 23, 7437-7439.	7.0	1
608	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. Cancer Biology and Therapy, 2018, 19, 97-100.	3.4	1
609	Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32.. Drug Metabolism Letters, 2018, 12, 153-153.	0.8	1
610	Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?. BJU International, 2019, 124, 549-550.	2.5	1
611	Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. ACS Medicinal Chemistry Letters, 2020, 11, 1711-1716.	2.8	1
612	Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa. AIDS Reviews, 2021, 23, 13-27.	1.0	1

#	Article	IF	Citations
613	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 2021, 39, e17044-e17044.	1.6	1
614	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. , 2000, 14, 338.		1
615	Whole or Partial Vessel Outgrowth Assays. , 0, , 105-121.		1
616	Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 2080-2080.	1.4	1
617	Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study. Blood, 2016, 128, 3339-3339.	1.4	1
618	Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft.. Journal of Clinical Oncology, 2012, 30, 4671-4671.	1.6	1
619	Androgen receptor and HIF-1Î± interaction in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 197-197.	1.6	1
620	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. Journal of Clinical Oncology, 2013, 31, 128-128.	1.6	1
621	A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, TPS5095-TPS5095.	1.6	1
622	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 4543-4543.	1.6	1
623	Percutaneous hepatic perfusion with melphalan for unresectable liver metastasis. Hepatoma Research, 2016, 2, 197.	1.5	1
624	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.. Journal of Clinical Oncology, 2020, 38, 3553-3553.	1.6	1
625	Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 189-193.	0.4	1
626	Single whole genome sequencing analysis blazes the trail for precision medicine. Cancer Biology and Therapy, 2022, 23, 134-135.	3.4	1
627	Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted. Cancers, 2022, 14, 1131.	3.7	1
628	Subcutaneous Atezolizumab: A Jab Without a Benefit. Clinical Pharmacology in Drug Development, 2022, 11, 134-135.	1.6	1
629	Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.. Journal of Clinical Oncology, 2022, 40, e17033-e17033.	1.6	1
630	Nitrate Tolerance: Does Tid Isosorbide Dinitrate Mean Dosing Every Eight Hours?. DICP: the Annals of Pharmacotherapy, 1991, 25, 1272-1273.	0.2	0

#	Article	IF	Citations
631	Epidemiology of drug interactions in cancer patients. Nature Reviews Cancer, 2006, 6, 824-824.	28.4	0
632	Assessing Progress Against Prostate Cancer. Clinical Genitourinary Cancer, 2006, 5, 102-103.	1.9	0
633	DNA microarrays: Tissue removal and processing affects gene expression. Cancer Biology and Therapy, 2006, 5, 1608-1609.	3.4	0
634	Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients. Cancer Biology and Therapy, 2007, 6, 318-319.	3.4	0
635	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. BJU International, 2007, 100, 1245-1248.	2.5	0
636	PD-0020 Pharmacokinetic Analysis of Percutaneous Hepatic Perfusion (PHP) of Melphalan in Patients with Hepatic Metastases from Melanoma. Annals of Oncology, 2012, 23, iv25-iv26.	1.2	0
637	Challenges in overcoming hormonal resistance in prostate cancer. Clinical Investigation, 2014, 4, 153-162.	0.0	0
638	New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer. Cancer Biology and Therapy, 2015, 16, 1702-1703.	3.4	0
639	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. Cancer Biology and Therapy, 2015, 16, 201-203.	3.4	0
640	Gene expression analysis enables repositioning of mithramycin for precision medicine inhibition of cancer stem cell signaling in thoracic malignancies. Journal of the American College of Surgeons, 2015, 221, e128-e129.	0.5	0
641	YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: â€œHippo-theticalâ€, new therapeutic targets?. Cancer Biology and Therapy, 2016, 17, 592-594.	3.4	0
642	Resisting resistance: Establishing new treatment options for CRPC patients. Cancer Biology and Therapy, 2016, 17, 337-338.	3.4	0
643	A new predictive tool for postoperative radiotherapy in prostate cancer. Cancer Biology and Therapy, 2017, 18, 277-278.	3.4	0
644	Mapping a path for cancer precision medicine. Lancet Oncology, The, 2017, 18, 1444.	10.7	0
645	A simple and rapid UHPLCâ€“MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. Journal of Pharmaceutical and Biomedical Analysis, 2017, 132, 223-226.	2.8	0
646	How do you take your coffee?. Lancet Oncology, The, 2019, 20, 913-914.	10.7	0
647	Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. Cancer Biology and Therapy, 2020, 21, 782-784.	3.4	0
648	A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).. Journal of Clinical Oncology, 2021, 39, TPS5090-TPS5090.	1.6	0

#	Article	IF	Citations
649	Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.. Blood, 2004, 104, 2406-2406.	1.4	0
650	Association between variants on 8q24 and prostate cancer: A review and meta-analysis.. Journal of Clinical Oncology, 2012, 30, 28-28.	1.6	0
651	Effect of thalidomide on the TGFÎ²-1-mediated synthesis of testosterone from DHEA in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 141-141.	1.6	0
652	Disruption of the HIFâ€1Î±/p300 interaction as a means of inhibiting angiogenesis. FASEB Journal, 2012, 26, 613.3.	0.5	0
653	Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients.. Journal of Clinical Oncology, 2012, 30, 3042-3042.	1.6	0
654	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. Journal of Clinical Oncology, 2014, 32, 211-211.	1.6	0
655	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 218-218.	1.6	0
656	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5074-5074.	1.6	0
657	Development of a CYP1B1*3 genotyping assay and mechanism of action studies related to docetaxel treatment in CRPC.. Journal of Clinical Oncology, 2014, 32, e16036-e16036.	1.6	0
658	Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects. Blood, 2014, 124, 3476-3476.	1.4	0
659	Tremelimumab: A monoclonal antibody against CTLA-4â€"In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. Journal of Clinical Oncology, 2017, 35, 88-88.	1.6	0
660	A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.. Journal of Clinical Oncology, 2018, 36, TPS11586-TPS11586.	1.6	0
661	Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.. Journal of Clinical Oncology, 2019, 37, e16554-e16554.	1.6	0
662	BETting on next-generation bromodomain inhibitors. American Journal of Clinical and Experimental Urology, 2020, 8, 129-132.	0.4	0
663	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. Blood, 2021, 138, 2457-2457.	1.4	0
664	Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2021, 138, 1815-1815.	1.4	0
665	Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2020, 136, 18-19.	1.4	0
666	Prostate cancer - 6th International Congress. IDrugs: the Investigational Drugs Journal, 2006, 9, 675-8.	0.7	0

#	Article	IF	Citations
667	OP059: Clinical impact of a targeted pharmacogenomic assessment within a cohort of individuals with suspected inborn errors of immunity. Genetics in Medicine, 2022, 24, S385.	2.4	0
668	Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application. Journal of Pharmaceutical and Biomedical Analysis, 2022, 213, 114685.	2.8	0
669	HIF-prolyl-hydroxylase 2 clinical inhibitor complex structure and XChem fragment-based screen obtained with succinate co-product used as a crystallisation tool. Acta Crystallographica Section A: Foundations and Advances, 2021, 77, C1193-C1193.	0.1	0
670	PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 2022, 40, e17046-e17046.	1.6	0